CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes

doi:10.1007/s11684-016-0443-1

Front. Med.

2016, Vol. 10

Issue (2) : 204-211 https://doi.org/10.1007/s11684-016-0443-1

RESEARCH ARTICLE

CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes

Jiangnan Liu^1,²,Bin Yi^1,²,Zhe Zhang^1,²,Yi Cao^1,^*(

)

¹. Laboratory of Molecular and Experimental Pathology, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, China
². Kunming College of Life Science, University of Chinese Academy of Sciences, Kunming 650223, China

Download: PDF(1013 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

CD176 (Thomsen-Friedenreich antigen) is a tumor-associated carbohydrate epitope (glycotope) functionally involved in blood spread and liver metastasis of cancer cells by mediating the adhesion of cancer cells to endothelial cells and hepatocytes, respectively. CD176 could be a promising target for antitumor immunotherapy. We applied B lymphocytes obtained from mice immunized with CD176 antigen and constructed a phage display library. A positive clone of CD176 single-chain variable antibody fragment (scFv) was successfully screened from this library. The CD176 scFv was expressed in Escherichia coli and purified. The purified scFv can bind to the natural CD176 expressed on the surface of cancer cells. Furthermore, the CD176 scFv inhibits the adhesion of CD176⁺ cancer cells to endothelial cells and hepatocytes. This CD176 scFv provides a basis for future development of recombinant CD176-specific antibodies that can be used in therapeutic application.

Keywords CD176 Thomsen-Friedenreich antigen scFv cancer therapy adhesion metastasis

Corresponding Author(s): Yi Cao

Just Accepted Date: 29 March 2016 Online First Date: 18 April 2016 Issue Date: 27 May 2016

Cite this article:

Jiangnan Liu,Bin Yi,Zhe Zhang, et al. CD176 single-chain variable antibody fragment inhibits the adhesion of cancer cells to endothelial cells and hepatocytes[J]. Front. Med., 2016, 10(2): 204-211.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-016-0443-1
https://academic.hep.com.cn/fmd/EN/Y2016/V10/I2/204

Fig.1 The binding ability of phage display CD176 scFv to antigens. The displayed CD176 scFv against CD176 (TF-PAA) (A) and aGP (B) was detected by ELISA. CD176 (TF-PAA) and aGP were coated on 96-plates (200 ng/well). M13KO7 helper phage was used as a negative control and CD176 mAb (IgM) as a positive control (mean±SD, n = 3).

Fig.2 Construction, expression, and purification of the CD176 scFv. (A) Expression of the CD176 scFv fusion protein was detected by SDS-PAGE (lines 1?4). Lines 1 and 2 were the suspense and sediment of lysis after induction with IPTG, respectively. Lines 3 and 4 were the suspense and sediment of lysis without IPTG induction, respectively. PET32a(+) was used as the control (lines 5?8). Lines 5 (suspense) and 6 (sediment) showed expressed results of PET32a(+) vector with IPTG induction, whereas lines 7 (suspense) and 8 (sediment) showed expressed results without IPTG induction. (B) Line 1 showed the CD176 scFv fusion protein after nickel-affinity purification; lines 2?5 showed the CD176 scFv fusion protein digested by enterokinase in 16, 24, 36, and 48 h, respectively. (C) The digested protein sample (scFv) was purified by IEC and yielded 11 protein fractions. All fractions were subjected to SDS-PAGE. (D) The result of the highest fraction, as demonstrated by SDS-PAGE. Line 1 is the fusion protein before purification and line 2 is the digested protein after purification.

Fig.3 Biological characteristics of the CD176 scFv. The binding of the purified CD176 scFv to the natural CD176 on the surfaces of cancer cells was shown (A and B). (A) Flow cytometry analysis showed that the scFv bound to KG1 cells (middle) compared with the controls [incubation with BSA (left) and irrelevant scFv (right)]. (B) The scFv reacted with CD176⁺ cell lines by immunofluorescence staining, and a CD176 mAb (IgM) was used as the positive control. The adhesion of CD176⁺ cancer cells to HUVEC and HL-7702 was inhibited by the CD176 scFv (C?E). (C) The adhesion of FITC-labeled SGC7901 cells to HUVEC was suppressed by the CD176 scFv (scFv) at different incubation times compared with the negative control (control). The inhibition effects of the CD176 scFv were semiquantitatively analyzed by luciferase assay (D, E). The adhesion of SW480 and SGC7901 to HUVEC (D) and HL-7702 (E) were inhibited significantly by the CD176 scFv compared with negative controls (control scFv and no treatment). y-axis is mean intensity fluorescence (mean±SD, n = 4).

1	Little M, Kipriyanov SM, Le Gall F, Moldenhauer G. Of mice and men: hybridoma and recombinant antibodies. Immunol Today 2000; 21(8): 364–370 https://doi.org/10.1016/S0167-5699(00)01668-6 pmid: 10916138
2	Dübel S. Recombinant therapeutic antibodies. Appl Microbiol Biotechnol 2007; 74(4): 723–729 https://doi.org/10.1007/s00253-006-0810-y pmid: 17225094
3	Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U. Thomsen-Friedenreich antigen: the “hidden” tumor antigen. Adv Exp Med Biol 2003; 535: 147–162 https://doi.org/10.1007/978-1-4615-0065-0_10 pmid: 14714894
4	Cao Y, Merling A, Karsten U, Schwartz-Albiez R. Expression of Thomsen-Friedenreich-related carbohydrate antigens on human leukemia cells. In: Mason D et al. Leucocyte Typing VII. Oxford: Oxford University Press, 2002; 204–205
5	Cao Y, Stosiek P, Springer GF, Karsten U. Thomsen-Friedenreich-related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 1996; 106(2): 197–207 https://doi.org/10.1007/BF02484401 pmid: 8877380
6	Lin WM, Karsten U, Goletz S, Cheng RC, Cao Y. Expression of CD176 (Thomsen-Friedenreich antigen) on lung, breast and liver cancer-initiating cells. Int J Exp Pathol 2011; 92(2): 97–105 https://doi.org/10.1111/j.1365-2613.2010.00747.x pmid: 21070402
7	Glinsky VV, Glinsky GV, Rittenhouse-Olson K, Huflejt ME, Glinskii OV, Deutscher SL, Quinn TP. The role of Thomsen-Friedenreich antigen in adhesion of human breast and prostate cancer cells to the endothelium. Cancer Res 2001; 61(12): 4851–4857 pmid: 11406562
8	Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF, Schlag PM. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A reevaluation. Cancer 1995; 76(10): 1700–1708 https://doi.org/10.1002/1097-0142(19951115)76:10<1700::AID-CNCR2820761005>3.0.CO;2-Z pmid: 8625037
9	Cao Y, Merling A, Karsten U, Goletz S, Punzel M, Kraft R, Butschak G, Schwartz-Albiez R. Expression of CD175 (Tn), CD175s (sialosyl-Tn) and CD176 (Thomsen-Friedenreich antigen) on malignant human hematopoietic cells. Int J Cancer 2008; 123(1): 89–99 https://doi.org/10.1002/ijc.23493 pmid: 18398838
10	Yi B, Zhang M, Schwartz-Albiez R, Cao Y. Mechanisms of the apoptosis induced by CD176 antibody in human leukemic cells. Int J Oncol 2011; 38(6): 1565–1573 pmid: 21455576
11	Yi B, Zhang Z, Zhang M, Schwartz-Albiez R, Cao Y. CD176 antiserum treatment leads to a therapeutic response in a murine model of leukemia. Oncol Rep 2013; 30(4): 1841–1847 pmid: 23900643
12	Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228(4705): 1315–1317 https://doi.org/10.1126/science.4001944 pmid: 4001944
13	Chan CE, Lim AP, MacAry PA, Hanson BJ. The role of phage display in therapeutic antibody discovery. Int Immunol 2014; 26(12): 649–657 https://doi.org/10.1093/intimm/dxu082 pmid: 25135889
14	McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990; 348(6301): 552–554 https://doi.org/10.1038/348552a0 pmid: 2247164
15	Larsen SA, Meldgaard T, Lykkemark S, Mandrup OA, Kristensen P. Selection of cell-type specific antibodies on tissue-sections using phage display. J Cell Mol Med 2015; 19(8): 1939–1948 https://doi.org/10.1111/jcmm.12568 pmid: 25808085
16	Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23(9): 1126–1136 https://doi.org/10.1038/nbt1142 pmid: 16151406
17	Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol 2005; 23(9): 1105–1116 https://doi.org/10.1038/nbt1126 pmid: 16151404
18	Karsten U, Butschak G, Cao Y, Goletz S, Hanisch FG. A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen. Hybridoma 1995; 14(1): 37–44 https://doi.org/10.1089/hyb.1995.14.37 pmid: 7539400
19	Pini A, Viti F, Santucci A, Carnemolla B, Zardi L, Neri P, Neri D. Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J Biol Chem 1998; 273(34): 21769–21776 https://doi.org/10.1074/jbc.273.34.21769 pmid: 9705314
20	Schirrmann T, Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 2010; 651: 177–209 https://doi.org/10.1007/978-1-60761-786-0_11 pmid: 20686967
21	Yuasa N, Zhang W, Goto T, Sakaue H, Matsumoto-Takasaki A, Kimura M, Ohshima H, Tsuchida Y, Koizumi T, Sakai K, Kojima T, Yamamoto K, Nakata M, Fujita-Yamaguchi Y. Production of anti-carbohydrate antibodies by phage display technologies: potential impairment of cell growth as a result of endogenous expression. J Biol Chem 2010; 285(40): 30587–30597 https://doi.org/10.1074/jbc.M110.107284 pmid: 20667829
22	Arjmand R, Fard SS, Saberi S, Tolouei S, Khamesipour A, Hejazi SH. Antigenic profile of heat-killed versus thimerosal-treated Leishmania major using sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Adv Biomed Res 2015; 4(1): 128 https://doi.org/10.4103/2277-9175.158068 pmid: 26261830
23	Madorsky Rowdo FP, Baron A, Urrutia M, Mordoh J. Immunotherapy in cancer: a combat between tumors and the immune system; you win some, you lose some. Front Immunol 2015; 6: 127 https://doi.org/10.3389/fimmu.2015.00127 pmid: 25859247
24	Fleuren ED, Versleijen-Jonkers YM, Heskamp S, van Herpen CM, Oyen WJ, van der Graaf WT, Boerman OC. Theranostic applications of antibodies in oncology. Mol Oncol 2014; 8(4): 799–812 https://doi.org/10.1016/j.molonc.2014.03.010 pmid: 24725480
25	Rabu C, McIntosh R, Jurasova Z, Durrant L. Glycans as targets for therapeutic antitumor antibodies. Future Oncol 2012; 8(8): 943–960 https://doi.org/10.2217/fon.12.88 pmid: 22894669
26	Fujita-Yamaguchi Y. Production of single-chain variable-fragments against carbohydrate antigens. Antibodies (Basel) 2014; 3(1): 155–168 https://doi.org/10.3390/antib3010155
27	Ravn P, Stahn R, Danielczyk A, Faulstich D, Karsten U, Goletz S. The Thomsen-Friedenreich disaccharide as antigen for in vivo tumor targeting with multivalent scFvs. Cancer Immunol Immunother 2007; 56(9): 1345–1357 https://doi.org/10.1007/s00262-007-0292-5 pmid: 17310382
28	Yuasa N, Koyama T, Fujita-Yamaguchi Y. Purification and refolding of anti-T-antigen single chain antibodies (scFvs) expressed in Escherichia coli as inclusion bodies. Biosci Trends 2014; 8(1): 24–31 https://doi.org/10.5582/bst.8.24 pmid: 24647109
29	Cao Y, Schlag PM, Karsten U. Immunodetection of epithelial mucin (MUC1, MUC3) and mucin-associated glycotopes (TF, Tn, and sialosyl-Tn) in benign and malignant lesions of colonic epithelium: apolar localization corresponds to malignant transformation. Virchows Arch 1997; 431(3): 159–166 https://doi.org/10.1007/s004280050083 pmid: 9334836

[1]

FMD-16209-of-CY_suppl_1

Download

[1]	Maura Massimino, Marta Podda, Lorenza Gandola, Emanuele Pignoli, Ettore Seregni, Carlo Morosi, Filippo Spreafico, Andrea Ferrari, Emilia Pecori, Monica Terenziani. Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma/PNET and Hodgkin lymphoma: a prospective cohort study[J]. Front. Med., 2021, 15(1): 101-107.
[2]	Yong Fan, Yan Geng, Lin Shen, Zhuoli Zhang. Advances on immune-related adverse events associated with immune checkpoint inhibitors[J]. Front. Med., 2021, 15(1): 33-42.
[3]	Solmaz Ohadian Moghadam, Seyed Ali Momeni. Human microbiome and prostate cancer development: current insights into the prevention and treatment[J]. Front. Med., 2021, 15(1): 11-32.
[4]	Hongnan Mo, Binghe Xu. Progress in systemic therapy for triple-negative breast cancer[J]. Front. Med., 2021, 15(1): 1-10.
[5]	Ching-Hon Pui. Precision medicine in acute lymphoblastic leukemia[J]. Front. Med., 2020, 14(6): 689-700.
[6]	Mian Peng, Xueyan Liu, Jinxiu Li, Di Ren, Yongfeng Liu, Xi Meng, Yansi Lyu, Ronglin Chen, Baojun Yu, Weixiong Zhong. Successful management of seven cases of critical COVID-19 with early noninvasive–invasive sequential ventilation algorithm and bundle pharmacotherapy[J]. Front. Med., 2020, 14(5): 674-680.
[7]	Pengju Zhang, Tao Li, Xingyun Wu, Edouard C. Nice, Canhua Huang, Yuanyuan Zhang. Oxidative stress and diabetes: antioxidative strategies[J]. Front. Med., 2020, 14(5): 583-600.
[8]	Ke Sheng. Artificial intelligence in radiotherapy: a technological review[J]. Front. Med., 2020, 14(4): 431-449.
[9]	Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu. Development of oncolytic virotherapy: from genetic modification to combination therapy[J]. Front. Med., 2020, 14(2): 160-184.
[10]	Jie Pan, Zhengchao Shi, Dingsai Lin, Ningmin Yang, Fei Meng, Lang Lin, Zhencheng Jin, Qingjie Zhou, Jiansheng Wu, Jianzhong Zhang, Youming Li. Is tailored therapy based on antibiotic susceptibility effective ? A multicenter, open-label, randomized trial[J]. Front. Med., 2020, 14(1): 43-50.
[11]	Jiahui Xu, Qianqian Wang, Elaine Lai Han Leung, Ying Li, Xingxing Fan, Qibiao Wu, Xiaojun Yao, Liang Liu. Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer[J]. Front. Med., 2020, 14(1): 60-67.
[12]	Jiajia Hu, Wenbin Shen, Qian Qu, Xiaochun Fei, Ying Miao, Xinyun Huang, Jiajun Liu, Yingli Wu, Biao Li. NES1/KLK10 and hNIS gene therapy enhanced iodine-131 internal radiation in PC3 proliferation inhibition[J]. Front. Med., 2019, 13(6): 646-657.
[13]	Rui Zhou, Yuanshu Liu, Wenjun Huang, Xitong Dang. Potential functions of esophageal cancer-related gene-4 in the cardiovascular system[J]. Front. Med., 2019, 13(6): 639-645.
[14]	Tianyuan Li, Renbing Jia, Xianqun Fan. Classification and treatment of orbital venous malformations: an updated review[J]. Front. Med., 2019, 13(5): 547-555.
[15]	Hong Zhang, Ying Chang, Qingqing Zheng, Rong Zhang, Cheng Hu, Weiping Jia. Altered intestinal microbiota associated with colorectal cancer[J]. Front. Med., 2019, 13(4): 461-470.

Viewed

Full text

Abstract

Cited

Shared

Discussed